Reviva Pharmaceuticals to Present at the Lytham Partners

CUPERTINO, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical firm growing therapies that search to deal with unmet medical wants in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory ailments, immediately introduced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will current at the Lytham Partners Fall 2022 Investor Conference being held September 28–29, 2022 and invitations buyers to take part through digital one-on-one conferences. Please see extra particulars beneath:

Management can be collaborating in digital one-on-one conferences all through the occasion. To organize a gathering with administration, please contact Lytham Partners at 1×[email protected] or register at https://www.lythampartners.com/fall2022invreg/.

About Reviva 
Reviva is a clinical-stage biopharmaceutical firm that discovers, develops and seeks to commercialize next-generation therapeutics for ailments representing unmet medical wants and burdens to society, sufferers, and their households. Reviva’s present pipeline focuses on the central nervous system, respiratory and metabolic ailments. Reviva’s pipeline at the moment contains two drug candidates, RP5063 (brilaroxazine) and RP1208. Both are new chemical entities found in-house. Reviva has been granted composition of matter patents for each RP5063 and RP1208 in the United States (U.S.), Europe, and several other different international locations.

https://ir.revivapharma.com/

Forward-Looking Statements 
This press launch incorporates sure forward-looking statements inside the that means of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, together with these relating to the Company’s product improvement, scientific and regulatory timelines and bills, market alternative, capability to elevate ample funding, aggressive place, attainable or assumed future outcomes of operations, business methods, potential development alternatives and different statements which can be predictive in nature. These forward-looking statements are primarily based on present expectations, estimates, forecasts and projections about the trade and markets through which we function and administration’s present beliefs and assumptions. These statements could also be recognized by the use of forward-looking expressions, together with, however not restricted to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and related expressions and the negatives of these phrases. These statements relate to future occasions or our monetary efficiency and contain identified and unknown dangers, uncertainties, and different elements which can trigger precise outcomes, efficiency or achievements to be materially completely different from any future outcomes, efficiency or achievements expressed or implied by the forward-looking statements. Such elements embrace these set forth in the Company’s filings with the Securities and Exchange Commission. Prospective buyers are cautioned not to place undue reliance on such forward-looking statements, which converse solely as of the date of this press launch. The Company undertakes no obligation to publicly replace any forward-looking assertion, whether or not because of new data, future occasions or in any other case.

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
[email protected]

Investor Relations Contact:
Lytham Partners, LLC
Ben Shamsian
[email protected]